



Single Day Event

Kishore Kumar
Consilx Digital PTE Ltd

Technology Enablement for Decentralized Clinical Trials

phuse.global



Highlighting Known Data Points ...

**1 out of 2
Investigators
participate in
clinical research
only once**

**Less than 5% of
patients
participate in
clinical research**

**30% patients
screened, fail to
meet study-
specific protocol
requirements**

**48% of studies
take significantly
longer time to
meet enrolment
targets**

**70% patients live
more than 2 hours
of travel from
research site**

**In 50% of trials,
patients find it
difficult to stay
enrolled due to
poor health**

**About 20% of
patients drop out
in clinical trials**

**85% of clinical
trials fail to retain
enough patients**



Decentralized Clinical Trial

Virtual

Digital

Remote

Site-less

Direct-to-Patient

GOAL


Make Clinical Trial
Easier for Patients,
Caregivers and
Industry

- **Patient Centricity**
- **Population Diversity**
- **Patient Recruitment**
- **Patient Retention**
- **Remote Data Collection**
- **Reduced SDVs**
- **Additional Capacity at Site**

Decentralization is a transformational philosophy for the conduct of clinical trials; fewer in-clinic visits; patient and caregiver burden is reduced; and a wide range of digital technologies deployed



Traditional Clinical Trial Is Site-centric





Patient-centric Decentralized Clinical Trial

Decentralisation does not mean


- absence of healthcare professionals
- eliminating physical patient contact

It is about looking at areas where digital technology, mix of in-clinic & tele-visits, and other novel solutions can help



Regulator's view

- More frequent, sensitive, and objective measures from digital tech help teams answer research questions faster and cheaper.





Technology Solutions Around The Patient



Site-Based




Home-Based

● Consent		eConsent
● IMP		Direct To Patient IMP
● Follow-up Visits		Text / Video Chats / Tele-visits
● Vital Signs		Devices / Wearables
● Paper Questionnaire		ePRO / eCOA
● Sample Collection		Home Health Nurse
● Adverse Events		eAdverse Events Reporting



Reduce The Burden For Both Patient & Site

Patient-Centric Study Conduct Infrastructure



1

Patient / Caregiver lands
on eRecruitment App
via digital lead gen


Uses search criteria
to identify trials

Doesn't find a trial - given
an option to opt-in for
future matching

Finds a trial, if key criteria is
met, expresses willingness
to join trial

Notified as soon as
additional trials matching
trial is available

Patient is then onboarded
on e-consent portal





2

The PHUSE Blockchain Phase II Project (Report dated 02 Dec 2020)

PoC study for accessing and sharing sensitive
patient data for pre-screening of patients for
clinical trial participation

Use Case: Patient recruitment for clinical trials





**Perceived
barriers
towards
adoption**

Literacy


Tech Savviness

Confidentiality, Integrity

Cost Effectiveness

Survey conducted by Tufts on impact of Covid-19 on future of trial execution


Utilization of Remote Technologies and Patient-centric Approaches





eConsent Platform: Quick View

**Increase
Comprehension**







Patient Engagement Apps

Influence Behaviour



Visits Trackers

Confirming a
Planned Visit,
Rescheduling,
Visit Instructions



Study Medications


Reminders,
Confirmation



Benefits of DCTs

Patient centricity is recognized as the biggest asset of a decentralized study

Main benefit for the adoption of DCT




Source: Informa Connect; NEJM Catalyst




Direct Data Collection Solutions

**Remote, Real-time,
Accurate Data**

- eSource
- Adverse events alerts
- Patient diaries
- Questionnaires
- QoL
- Surveys
- Symptoms
- Images
- Videos
- Devices
- Wearables
- Lab / 3rd parties




Technologies used in current DCTs



Source: Informa Connect; CTTI

What is the most important aspect to consider when deciding on technology?



Source: Informa Connect; CTTI



IRB Approved Proof of Value Study Conducted By HITLAB, A Digital Health Research Lab (Nov 2008)

Patients

In numbers

- **75%** participants needed no support to setup
- **87%** patients completed consent remotely
- **86%** compliance to completing questionnaires
- **75%** medication adherence reporting

What worked?

- Usability: navigation, understanding, layout
- Perform trial activities remotely
- In-app activities, reminders promoted adherence
- AE reporting feature preferred over other methods
- Viewing own data drives engagement & retention: one place, immediate access, share with care providers
- Security element of blockchain made users feel more comfortable and secure

Recommendations

- 100% interested in owning their medical records
- 86% interested in sharing data with other trials
- Additional features: Payment, site travel logistics

87% participants would recommend LifeLedger™ for future clinical trials

Investigators

What worked?

- Usability: dashboards, navigation. Even for less technically-savvy
- eConsent and re-consent feature. Blockchain expected to address security concerns.
- Expect patient adherence and retention to improve
- AE alert feature and timestamping helps track timely responsiveness
- Real time data hit all the right points
- Record events electronically (including visits), connect with other devices enhances overall PX
- Reduces paper storage
- Real time research allows changes in protocol as needed

Recommendations

- Tailoring dashboard, data collection fields and app for specific populations will improve adoption
- Timestamping when data is submitted would be useful information

Expressed desire to extend the app to their clinical trials

Sponsors

What worked?

- Delivers value to clinical trial sponsorship
- Blockchain helpful to solve known impediments to data-driven clinical trials.
- Reporting AE is an important tool and will help sponsors to understand safety issues quickly
- With blockchain, one can verify the sources of the data and where its coming from including reproducibility
- Data immutability and provenance are important to the sponsor
- The big benefit is the regulatory authorities could take the audit from this product at face value
- LifeLedger™ could potentially save significant money in streamlining the auditing process

LifeLedger™ can help make trial auditing faster with significant savings



eConsent Deployment In A COVID-19 Sero-prevalence Community Study (Aug 2020)

Mumbai City

3 Slum Areas

3 Non-slum Areas

75 Field Volunteers

14 Days of Field Work



12,663 Participants Registered

8,142 Consented

The Solution

eConsent App

- Multiple languages
- Multi-media support
- LAR option
- Off-line data capture
- Data sharing
- KPI dashboard



Outcomes Delivered

- Successful identification and enrolment of eligible volunteers for the survey
- Digital process delivering operational efficiency in large scale community-based survey
- Real-time sharing of signed informed forms (pdf) with subjects through whatsapp / email
- Real-time SMS notification on subjects mobile phones about their consenting status
- Reports for daily reconciliation of subjects with lab database
- Performance reports within an hour post completion of survey for management review
- Test results shared with subjects within 3 days post sample collection
- Target (8000) achieved in 14 days; significantly lesser duration compared with previous rounds by the same sponsor using paper-based consenting process



An Open-label Safety & Acceptability Study Of A Medical Device on 30 Volunteers

(Feb 2021)



	Visit #1	Visit #2	Visit #3	Visit #4	Visit #5
Protocol-defined Location	In-Clinic 	In-Clinic 	At-Home 	At-Home 	At-Home 
Procedures	Consent Screening	Enrolment Baseline assessments IP administration Pain assessment Acceptability questionnaire AE assessment	Follow-up visit Pain assessment AE assessment	Follow-up visit Pain assessment AE assessment	Follow-up visit Pain assessment AE assessment
Solution / platform used	eConsent eSource	eSource Direct data collection tools	Tele-visit Text & Video chat eSource eQuestionnaire	Tele-visit Text & Video chat eSource eQuestionnaire	Tele-visit Text & Video chat eSource eQuestionnaire

Outcomes

- Digitized all components involved in the conduct of the hybrid study (consent, data collection, acceptability, safety & pain assessments)
- Seamless experience in onboarding volunteers, executing consent at site, sharing the signed consent form with the volunteers on email
- Online data collection using eSource modules and real-time insights on missed data or if there were any issues
- Subjects completed pain assessment electronically – VAS; all data points related to timing of administration & measurements are tracked
- Tele-visit was successfully used to contact the subject for visits #3, #4, & #5 and AE assessments
- Effective coordination of multiple In-clinic and Tele-visits; real-time data visibility was well received by the study team and sponsor



Blockchain Technology Phase II Project Report (dated 02 Dec 2020)




Consilx led this project, lending technology from their end-to-end eConsenting platform. Consilx leveraged the SAAVHA patient ID and connected to the local site ID, ensuring documentation and updates surfaced in the user's dashboard and were fed back to sites to manage the appropriate patient on-boarding process.




Pandemic Accelerated Discussions On Decentralized Clinical Trials

Effect of COVID-19 on current DCT adoption




Likelihood of increasing DCT within next two years



79% of SPONSORS/CROs Increasing Virtual


How has COVID-19 and associated lockdowns impact your use of decentralized trials?



Clinical Trials Europe, May 2020, n=184

90% of PARTICIPANTS Impacted

What changes have you experienced in your clinical trial as a result of the COVID-19 pandemic?




CISCRP 2020, n=38



Adapting Decentralized Trials ...

Biggest challenges to overcome for running DCTs





Collaboration is the Key



Thank you ...



**The Global Healthcare
Data Science Community**

Contact Channels

📞 UK +44 1843 609600
📞 USA +1 609 514 5105
✉️ office@phuse.global
🌐 phuse.global

Social Media

🐦 [@phusetwitta](https://twitter.com/phusetwitta)
📘 [/phusebook](https://facebook.com/phusebook)
▶️ [/phusetube](https://youtube.com/phusetube)
🌐 [/company/phuse](https://linkedin.com/company/phuse)